News
The day at a glance · 3 min read
Mood · Risk-On
+68
Sentiment, −100 to +100
Eli Lilly 2026 Revenue Guidance
$85-87BRaised
Pfizer 1-Month Return
8.81%+8.81%
Expected LLY Q2 EPS
$6.58+4.3%
Key driverStrong Q2 earnings from major pharmaceutical companies and FDA approval of Moderna's influenza vaccine drove positive sector sentiment
Daily briefHealthcare· Money365.Market AI ·

Big Pharma Earnings Lift Sector; Moderna Wins FDA Approval

Eli Lilly raises guidance to $85-87B, Moderna secures fifth product approval, Schrödinger turns profitable on AI expansion

Big Pharma Earnings Wave

Bullish
01LLY
Eli Lilly ($LLY) reported strong Q2 results and raised full-year 2026 revenue guidance to $85-87B, driven by volume gains despite price declines. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The company's weight-loss drug franchise continues to drive outsized demand, though executives have acknowledged capacity constraints as a potential bottleneck to growth.
02PFE
Pfizer ($PFE) raised 2026 revenue guidance following its Q2 update, posting a 1-month share price return of 8.81% and a 1-year total shareholder return of 15.42% despite reporting a net loss and sizeable non-cash impairments. Analysis suggests $PFE could be 12% undervalued following the revised guidance and solid non-COVID product performance.
03AMGN
Amgen ($AMGN) raised guidance as rapid growth across cardiovascular, bone and rare-disease medicines offset the company's decision to abandon an obesity candidate.

FDA Approvals & Product Launches

Bullish

Moderna Approved Products

5 globally+New approval

Compass Pathways Cash

$433MReported Q2
01MRNA
Moderna ($MRNA) received FDA approval for its influenza vaccine mFLUSIVA, becoming the company's fifth approved product globally and fourth FDA-approved product. The company expects supply to be available in select retailers in the coming weeks.
02MRNA
$MRNA released its Q2 2026 earnings presentation alongside the approval announcement.
03CMPS
Compass Pathways ($CMPS) reported a cash position of $433 million and advanced its rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.

AI-Driven Drug Discovery Partnerships

Bullish

Schrödinger Q2 Revenue

$58.89MReported

Schrödinger Q2 Net Profit

$5.98M+Profitable shift

SDGR Share Performance

+8.5%+8.5%
SDGRBMY
01SDGR
Schrödinger Inc. ($SDGR) reported Q2 2026 revenue of $58.89 million and shifted to a net profit of $5.98 million, reversing prior losses. The company expanded its long-running collaboration with Bristol Myers Squibb ($BMY) to deploy its new agentic AI co-scientist platform, Bunsen, across Bristol Myers Squibb's research organization.
02SDGR
$SDGR shares rose 8.5% following the earnings release and partnership expansion.
03
Second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen.

International Pharma Results

Bullish

Merck KGaA Q2 Profit Growth

+9%+9%

Royalty Pharma Receipts Growth

+14%+14%
01MRK
Merck KGaA ($MRK) reported Q2 adjusted profit rose 9%, aided by strong performances in its life science and electronics divisions. The company raised its annual profit outlook following the stronger-than-expected quarterly results.
02RPRX
Royalty Pharma ($RPRX) reported 14% total receipts growth and raised full-year 2026 guidance for the second consecutive quarter.

Looking Ahead

Neutral
LLYCMPS
01
Healthcare stocks have lagged broader market performance this year, with a few sectors dominating gains, though analysts suggest many healthcare stocks appear ready to gain ground. The sector faces ongoing scrutiny around drug pricing policy and Medicare negotiations, though strong volume growth at major pharmaceutical companies has offset pricing pressures in recent quarters. Compass Pathways' targeted first-half 2027 launch of COMP360 represents a potential catalyst for the psychedelic therapeutics space, pending NDA completion and FDA review.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy